US OptionsDetailed Quotes

AVXL250117C9000

Watchlist

2.40
-0.45-15.79%

15min DelayClose Dec 24 13:00 ET

3.41High2.30Low

Anavex Life Sciences Stock Discussion

Rhiox

10 hours ago

$Anavex Life Sciences (AVXL.US)$ I just want to wish everyone a merry Christmas and happy holidays

Trytosaveabit

Yesterday 04:54

I know it’s not as exciting as a runner! Hehehe

$Anavex Life Sciences (AVXL.US)$ But ive been all by my lonesome here today! HUMPFFF! Hehehe

Trytosaveabit

Dec 23 06:11

Update

$Anavex Life Sciences (AVXL.US)$ Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

Moo Earnings

Dec 23 02:12

Weekly Earnings Preview (12.23-12.27)

Hi mooers!
Need a quick update on this week's events? Check out moomoo's fresh earnings & economic calendars to start this week!
For more details, check out the earnings calendar and economic calendar!
This week, various companies including $Anavex Life Sciences (AVXL.US)$ , $Limoneira (LMNR.US)$ and $Venu Holding (VENU.US)$ are releasing their earnings. How will the market react to the companies' results? Let's keep our eyes peeled and see who will shine b...

Stock_Drift

Dec 22 18:46

🐮

$Limoneira (LMNR.US)$ $Venu Holding (VENU.US)$ $Anavex Life Sciences (AVXL.US)$

Daily Investors

Dec 20 08:01

Miss

$Anavex Life Sciences (AVXL.US)$ a Good Company, and def undervalued. They have done so much in the past 6 months. However where they are at, there not making money, just research

Rhiox

Dec 16 08:43

$Anavex Life Sciences (AVXL.US)$ crossing over mid Bollinger band on day chart , possible to see 9. + soon

Rhiox

Dec 13 15:48

$Anavex Life Sciences (AVXL.US)$
$Sunshine Biopharma (SBFM.US)$
$Rumble (RUM.US)$
Got a few superbouncy balls this evening.
making me dizzy 🤣

Rhiox

Dec 12 08:26

$Anavex Life Sciences (AVXL.US)$ 👀

Jaguar8

Dec 9 06:55

NEWS

$Anavex Life Sciences (AVXL.US)$
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Anavex Life Sciences (Nasdaq: AVXL) announced it will present new long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial for blarcamesine in early Alzheimer's disease at the J.P. Morgan 2025 Healthcare Conference. The presentation will showcase data from up to 144 weeks of continuous treatm...

No comment yet